No Data
No Data
Optimistic Outlook on Alto Neuroscience: Advancements in Precision Neuropsychiatry and Biomarker-Driven Treatments
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $10
Alto Neuroscience Announces Multiple Presentations Made At The Society of Biological Psychiatry Annual Meeting, In Toronto, Canada, Held April 24-26, 2025
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
H.C. Wainwright Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $10
Alto Neuroscience Initiated With a Buy at H.C. Wainwright